Jpmorgan Chase & CO Voyager Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 261,934 shares of VYGR stock, worth $1.48 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
261,934
Previous 275,443
4.9%
Holding current value
$1.48 Million
Previous $2.18 Million
29.66%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding VYGR
# of Institutions
130Shares Held
34.7MCall Options Held
39.7KPut Options Held
34.6K-
Black Rock Inc. New York, NY5.31MShares$30.1 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$29.4 Million0.5% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.92MShares$22.2 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.19MShares$18 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.29MShares$13 Million0.07% of portfolio
About Voyager Therapeutics, Inc.
- Ticker VYGR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,647,600
- Market Cap $219M
- Description
- Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...